How severe is CVE-2019-13157?

CVE-2019-13157 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity high, and availability none.

Is CVE-2019-13157 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (74th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2019-13157?

CVE-2019-13157 affects Naver Vaccine. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2019-13157?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2019-13157 published?

CVE-2019-13157 was published on 2019-11-22 and last updated on 2026-06-17.

CVE-2019-13157

CVE-2019-13157 is a high-severity vulnerability in Naver Vaccine with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-22.

Key facts

Severity: High (CVSS 3.x base score 7.5)
CVSS v2: 6.4
EPSS exploit prediction: 2% (74th percentile)
Actively exploited: Not listed in CISA KEV
Weakness: CWE-22
Affected product: Naver Vaccine
Published: 2019-11-22
Last modified: 2026-06-17

Description

nsGreen.dll in Naver Vaccine 2.1.4 allows remote attackers to overwrite arbitary files via directory traversal sequences in a filename within nsz archive.

Frequently asked questions

What is CVE-2019-13157?: nsGreen.dll in Naver Vaccine 2.1.4 allows remote attackers to overwrite arbitary files via directory traversal sequences in a filename within nsz archive.
How severe is CVE-2019-13157?: CVE-2019-13157 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity high, and availability none.
Is CVE-2019-13157 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (74th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2019-13157?: CVE-2019-13157 affects Naver Vaccine. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2019-13157?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2019-13157 published?: CVE-2019-13157 was published on 2019-11-22 and last updated on 2026-06-17.

References

https://cve.naver.com/detail/cve-2019-13157

Affected products (1)

cpe:2.3:a:naver:vaccine:2.1.4:*:*:*:*:*:*:*

Other CWE-22 (Path Traversal) vulnerabilities

CVE-2026-48282 — Critical (CVSS 10.0): ColdFusion versions 2025.9, 2023.20 and earlier are affected by an Improper Limitation of a Pathname to a Restricted…
CVE-2026-54917 — Critical (CVSS 10.0): SeaweedFS is a distributed storage system for object storage (S3), file systems, and Iceberg tables. Prior to 4.30, the…
CVE-2026-11429 — Critical (CVSS 10.0): Two endpoints in the Vault Service ScriptsController, shared by Altium Enterprise Server and Altium 365, accept file…
CVE-2026-34909 — Critical (CVSS 10.0): A malicious actor with access to the network could exploit a Path Traversal vulnerability found in UniFi OS devices to…
CVE-2026-7411 — Critical (CVSS 10.0): In Eclipse BaSyx Java Server SDK versions prior to 2.0.0-milestone-10, inadequate path normalization in the Submodel…
CVE-2026-36767 — Critical (CVSS 10.0): A path traversal vulnerability in the /content/images/add endpoint of shopizer v3.2.5 allows attackers write arbitrary…

Browse all CWE-22 (Path Traversal) vulnerabilities →